Toulose, France Clinical Trials

A listing of Toulose, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 130 clinical trials
Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

This is a Phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven patient cohorts for up to 603 previously treated and treatment-nave NSCLC patients. Cohorts 3 and 4 were added with Amendment 1 and three additional cohorts were added with Amendment 2 (Cohorts …

osimertinib
cancer chemotherapy
HER2
EGFR
stage iv non-small cell lung cancer
University Hospital Germans Trias i Pujol, Department of Medical Oncology
 (157.2 away) Contact site
  • 320 views
  • 13 May, 2021
  • +68 other locations
Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) prevail in older age and are characterized by ineffective erythropoiesis and peripheral cytopenias. Supportive therapy is the main therapeutic option for most patients. Quality of Life (QoL) is mainly deteriorated by anemia and by the limitations associated with thrombocytopenia, neutropenia and transfusion dependence. The only available treatment …

blood transfusion
myeloid leukemia
bone marrow procedure
filgrastim
colony stimulating factor
CHU de Haut-L v que
 (131.0 away) Contact site
  • 19 views
  • 23 Jan, 2021
  • +81 other locations
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin FlexPro ) in Growth Hormone Treatment na ve Pre-pubertal Children With Growth Hormone Deficiency

This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of once-weekly NNC0195-0092 (somapacitan) treatment compared to daily growth hormone treatment (Norditropin FlexPro) in growth hormone treatment nave pre-pubertal children with growth hormone deficiency. The trial consists of a 26 week main trial period, …

Novo Nordisk Investigational Site
 (2.0 away) Contact site
  • 38 views
  • 09 May, 2021
  • +56 other locations
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …

Investigational Site Number 7240001
 (154.0 away) Contact site
  • 485 views
  • 28 Jul, 2021
  • +51 other locations
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

multiple myeloma
measurable disease
CHU de Montpellier, Hopital Saint-Eloi
 (121.2 away) Contact site
  • 0 views
  • 30 Jul, 2021
  • +75 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or pancreatic cancer.

biliary tract cancer
estrogen receptor
programmed cell death 1 ligand 1
carcinoma
triple negative breast cancer
Hospital Clinic i Provincial ( Site 0703)
 (156.6 away) Contact site
  • 611 views
  • 28 Jul, 2021
  • +89 other locations
A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients

HB-101 is a bivalent recombinant vaccine against human CMV infection. This is a randomized, placebo-controlled, phase 2 study to assess the safety, reactogenicity, immunogenicity, and efficacy of HB-101 in CMV-Seronegative patients receiving a kidney transplant from a CMV-Seropositive living donor and CMV-Seropositive patients.Patients enrolled should have a living donor kidney …

kidney transplant
CHU de Toulouse - Hospital Rangueil
 (3.0 away) Contact site
  • 42 views
  • 08 May, 2021
  • +43 other locations
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.

peripheral t-cell lymphoma
oxaliplatin
fungal infection
skin lesion
t-cell lymphoma
CHRU de Montpellier - Hopital Saint Eloi
 (120.4 away) Contact site
  • 26 views
  • 12 Jun, 2021
  • +44 other locations
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

The purpose of this study is to compare the efficacy (rate of very good partial response [VGPR] or better as best response as defined by the International Myeloma Working Group [IMWG] criteria) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants …

corticosteroids
daratumumab
progressive disease
cell transplantation
bisphosphonate
CHU de Montpellier, Hopital Saint-Eloi
 (116.2 away) Contact site
  • 21 views
  • 22 Jul, 2021
  • +162 other locations
KRT-232 in Subjects With PMF Post-PV MF or Post-ET MF Who Have Failed a JAK Inhibitor

This study evaluates the efficacy in achieving clinical cure in non-bacteremic urinary tract infections (UTI) caused by Escherichia coli or Klebsiella pneumoniae producers of extended-spectrum -lactamases (ESBL) in adult patients. Half of participants will receive Piperacillin/Tazobactam as treatment, while the other half will receive Carbapenems. The investigators will verify that …

Institut Universitaire du Cancer de Toulouse Oncopole
 (0.5 away) Contact site
  • 134 views
  • 23 Jan, 2021
  • +90 other locations